Clinical Trial Imaging Market, By Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-Ray), By Product & Services (Software, Services), By End User (Pharmaceutical Companies, Biotechnology Companies, CROs, Medical Device Manufacturers), By Region (North America, Eastern Europe, Western Europe, Asia Pacific, Middle East, Rest Of The World) – Market Size & Forecast (2023-2032)

The Global Clinical Trial Imaging Market was valued at USD 1.62 Billion in 2021 and is expected to grow at a CAGR of 8.23% during the forecast period. Clinical trial imaging is a technique used in oncological clinical trials to provide evidence for decision making. It is a type of research, that studies new treatments and tests and evaluates their effects on human health outcomes.

The clinical trial imaging market is driven by increasing spending on research & development sectors for developing new drugs to treat diseases and growing focus on life science projects for diagnostics or new therapy.

Further, advanced radiology and other imaging systems involves high-cost investments for installation and maintenance and to hire expert professionals are required to operate the equipment, which can also be costly. These factors are expected to restrain the global clinical trial imaging market growth. Also, due to increasing prevalence of chronic diseases and increasing investments in R&D sectors are expected to create opportunities for market growth.

The trial imaging procedures involves high cost-structures for providing innovative treatments and innovative drugs development or therapy needs to go through a very expensive process. These factors are expected to pose a challenge to market players to operate in the global clinical trial imaging market.

Impact of COVID-19 on Global Clinical Trial Imaging Market

With increasing number of COVID-19 pandemic cases across the world, many ongoing trials, treatments or therapy were paused by the research institute during the initial stages, which had a negative impact in the market due to COVID-19. However, due to the rising need for drugs and vaccines, clinical trials were conducted thus meeting the need for vaccines/drugs. Hence, post mid-2020, the market has witnessed a positive impact and is also expected to witness positive impact during the forecast period.

 

Market Segmentation

The global clinical trial imaging market report has been segmented by software & services, modality, therapeutic areas, end user, and region.

FIGURE 1: GLOBAL CLINICAL TRIAL IMAGING MARKET SEGMENTATION

fig 1

Global Clinical Trial Imaging Market, by Software & Services

Based on software & services, the clinical trial imaging market is segmented into operational imaging and read analysis. Operational imaging segment dominates the market for global clinical trial imaging in 2021 and is expected to remain dominant during the forecast period.

Operational imaging includes various imaging process and technologies for the treatment of diseases such as medical imaging like as computed tomography (CT) scan, magnetic resonance imaging (MRI) or computerized axial tomography (CAT) scanners. With growing chronic and lungs diseases, demands for operational imaging is also increasing. This is expected to contribute to segment growth.

Global Clinical Trial Imaging Market, by Modality

Based on modality, the clinical trial imaging market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), x-ray, positron emission tomography (PET), echo cardiography, and others.

Computed tomography (CT) segment holds the largest market share for clinical trial imaging in 2021 and is expected to remain largest during the forecast period. Factors driving the segment growth are increasing investments in research & development sectors and increasing number of contract research organizations (CROs) with high growth rate in the biotechnology & pharmaceutical companies.

Global Clinical Trial Imaging Market, by Therapeutic Areas

Based on therapeutic areas, the global clonal trial imaging market is segmented into oncology, infectious, CNS, and CVS. Oncology segment holds the largest market share in 2021 and is estimated to remain largest during the forecast period.

Factors driving the segment growth are high demands of oncology for cancer treatments as oncology treatments help professionals to find new ways to prevent and detect cancer. Oncology treatments improve the quality of life for patients during and after their treatment process, as a result, the market segment for oncology is highly demanded and boosting the global clinical trial imaging market.

Global Clinical Trial Imaging Market, by End User

Based on end user, the market is segmented into biotechnology & pharmaceutical companies, contract research organizations (CROs), medical device manufacturers, academia & government research institutes, and others. Among these, biotechnology & pharmaceutical companies are dominating the global clinical trial imaging market in 2021, and is expected to remain largest during the forecast period.

Factors contributing to segment growth are rise in chronic diseases and the need to develop innovative drugs and therapies by biotechnology & pharmaceutical companies. Additionally, the recent strategic initiatives such as merger & acquisition and collaboration undertaken by major players will further drive the market growth.

Global Clinical Trial Imaging Market, by Region

Based on region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South America. North America is dominating the global clinical trial imaging market in 2021 and is estimated to remain dominant during the forecast period due to the presence of leading market players operating in this region, such as Radiant Sage LLC, Bio Telemetry, Inc and Medpace Holdings, Inc.

Additionally, with healthcare advancements and availability faster services for diagnosis and treatments for chronic diseases, government and biotechnology & pharmaceutical companies investments in clinical trial imaging sectors are increasing the regional market growth.

Also, increasing geriatric population along with growing chronic diseases as well as reasonable cost-structures for imaging procedures are playing an important role in the upliftment of North American market for clinical trial imaging.

 

Recent Developments in the Global Clinical Trial Imaging Market

  • August 2021 – NANOX Imaging Ltd. declared two agreements projected to create globally connected by end-to-end radiology solution. NANOX acquired Zebra Medical Vision and USARAD, are expected to set a new standard in the medical device sector.
  • January 2021 – Bioclinica announced invention of AI image redaction technology for clinical trials. The new product will support redaction of patient’s sensitive information from photos, videos, and PDFs in clinical trials.
  • January 2021 – Bioclinica acquired Silicon Valley-based Saliency to accelerate digital diagnostic development. Bioclinica merged with Saliency’s AI advanced technology to support increasing range of pharmaceutical and medical device clients.
  • December 2020 – ERT announced close merger with Bioclinica. The combination forms the global leader in clinical trial endpoint technology and leading partner to biotechnology & pharmaceutical companies by providing best-in-class technology with an unrelenting focus on customer service.

What Does This Report Provide?

This report provides a detailed understanding of the global clinical trial imaging market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market. The major market drivers, challenges, and opportunities for the global clinical trial imaging market have been covered in the report. This report further includes the market shares of the leading companies operating in the global market, along with their production capacities and the growth strategies adopted by them.

Market Segmentation:

By Software & Services:

  • Operational Imaging
  • Read Analysis

By Modality:

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • X-ray
  • Ultrasound
  • Positron Emission Tomography (PET)
  • Echo Cardiography
  • Others

By Therapeutic Areas:

  • Oncology
  • Infectious
  • Central Nervous System (CNS)
  • Chorionic Villus Sampling (CVS)

By End User:

  • Biotechnology & Pharmaceutical
  • Contract Research Organizations (CROs)
  • Medical Device Manufacturers
  • Academia & Government Research Institutes
  • Others

By Region:

North America Clinical Trial Imaging Market

  • North America, by Country
    • U.S.
    • Canada
    • Mexico
  • North America, by Software & Services
  • North America, by Modality
  • North America, by Therapeutic Areas
  • North America, by End User

Europe Clinical Trial Imaging Market

  • Europe, by Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe 
  • Europe, by Software & Services
  • Europe, by Modality
  • Europe, by Therapeutic Areas
  • Europe, by End User

Asia Pacific Clinical Trial Imaging Market

  • Asia Pacific, by Country
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia Pacific 
  • Asia Pacific, by Software & Services
  • Asia Pacific, by Modality
  • Asia Pacific, by Therapeutic Areas
  • Asia Pacific, by End User

Middle East and Africa Clinical Trial Imaging Market

  • Middle East and Africa, by Country 
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East and Africa
  • Middle East and Africa, by Software & Services
  • Middle East and Africa, by Modality
  • Middle East and Africa, by Therapeutic Areas
  • Middle East and Africa, by End User

South America Clinical Trial Imaging Market

  • South America, by Country 
    • Brazil
    • Argentina
    • Rest of South America
  • South America, by Software & Services
  • South America, by Modality
  • South America, by Therapeutic Areas
  • South America, by End User

Major Companies: In this report, the major companies studied are: Biomedical Systems Corporation, BioClinica Inc., Cardiovascular Imaging Technologies LLC, Prism Clinical Imaging, Inc., ProScan Imaging LLC, ICON plc, Bio Telemetry, Inc., Medpace Holdings, Inc., Paraxel International Corporation, Radiant Sage, Resonance Health, Navitas Life Sciences.

Objectives of this Report:

  • To estimate the market size for the clinical trial imaging market on a regional and global basis
  • To identify major segments in the clinical trial imaging market and evaluate their market shares and demand
  • To provide a competitive scenario for the clinical trial imaging market with major developments observed by the key companies in the historic years
  • To evaluate key factors governing the dynamics of clinical trial imaging market with their potential growth during the forecast period
  • To evaluate the leading company-wise pricing analysis for the mentioned applications

Key Questioned Answered in the Study:

  • What are major growth drivers and market trends that impacting on clinical trial imaging market?
  • What the market size both in terms of value and volume for clinical trial imaging market?
  • Who are leading market players and who are the new market players that operate in the global clinical trial imaging market with an estimated market share?
  • What are the future investment pockets and opportunity in the global clinical trial imaging market?
  • Major list of customers and potential futuristic customer list along with an estimated buying volume
  • Impact of COVID-19 on global clinical trial imaging market

Customization:

This study is customized to meet your specific requirements:

  • By sub-segment
  • By client-specific country, type, and application market analysis
  • Pricing analysis along with the potential list of customers
  • Product-specific competitive analysis

For more information, contact: sales@quincemarketinsights.com